David Hesse, MD
Urology · New Haven, CTNPI 1952343741
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,142 of the $4,001 with a category attached, or 78.5%. Covidien LP accounts for 78.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $3,142 and has fallen 95.9% since, to $128 in 2025.
Across 11 payments — averaging $363.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Covidien LP$3K
- Palette Life Sciences, Inc.$244
- Intuitive Surgical$193
- Urogen Pharma, Inc.$156
- Boston Scientific$138
- Johnson & Johnson$128
What the payments were for
- Consulting fees$3,14279%
- Travel & lodging$1935%
- Food & beverage$66117%
- Education$50%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Covidien LP | 2 | $3,142 |
| Palette Life Sciences, Inc. | 2 | $244 |
| Intuitive Surgical | 2 | $193 |
| Urogen Pharma, Inc. | 2 | $156 |
| Boston Scientific | 2 | $138 |
| Johnson & Johnson | 1 | $128 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vsiii$1,600
- Deflux$244
- Da Vinci Surgical System$187
- JELMYTO$150
- Erleada$128
How this compares
$4,001 in reported general payments places this provider in the 65th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 43 | $49,732 |
| GemtesaVibegron | 13 | $6,347 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 268 | $6,008 |
| Methenamine Hippurate | 37 | $5,782 |
| Tamsulosin Hcl | 407 | $5,694 |
| Tadalafil | 28 | $4,481 |
| Finasteride | 307 | $4,170 |
| Trospium Chloride | 32 | $2,364 |
| Oxybutynin Chloride ErOxybutynin Chloride | 73 | $2,021 |
| Dutasteride | 55 | $1,380 |
| Silodosin | 24 | $1,074 |
| Testosterone | 12 | $949 |
| Imipramine Hcl | 39 | $729 |
| Bicalutamide | 26 | $684 |
| Allopurinol | 22 | $333 |
Paid to pharmacies, not to this prescriber.
Other urology in New Haven
- Daniel KellnerNew Haven$122K
- Preston SprenkleNew Haven$57K
- Stanton HonigNew Haven$40K
- Michael LeapmanNew Haven$21K
- Jason LeeNew Haven$19K
- Leslie RickeyNew Haven$17K
- Gregory LacyNew Haven$11K
- Fady GhaliNew Haven$10K
- Guy ManettiNew Haven$7K
- Wei Shen TanNew Haven$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.